Skip to main content

Processa Pharmaceuticals, Inc.

PCSA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001533743

No open-market purchases or sales by Processa Pharmaceuticals, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $498.3K in total; no superinvestor holds it.

Q1 2023 vs. Q4 2022

How the institutions holding Processa Pharmaceuticals, Inc. changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of PCSA: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders1822+4
Shares1.16M1.65M+489.3K (+42.1%)
Value$1.28M$852.6K−$424.3K (−33.2%)

New holders (8)

Institutions that held Processa Pharmaceuticals, Inc. at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to PCSA in Q1 2023
InstitutionSharesValue% of portfolio
Walleye Capital LLC733,954$388.9K0.01%
Two Sigma Securities, LLC62,626$31.3K0.00%
Millennium Management LLC50,504$27.0K0.00%
UBS Group AG22,459$11.2K0.00%
Virtu Financial LLC12,949$7.00K0.00%
Jane Street Group, LLC10,040$5.02K0.00%
WealthPLAN Partners, LLC1,000$5000.00%
Farther Finance Advisors, LLC487$2440.00%

Sold out (4)

Institutions that held Processa Pharmaceuticals, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.

Institutions that sold out of PCSA in Q1 2023
InstitutionShares, Q4 2022Value, Q4 2022
AIGH Capital Management LLC303,703$334.1K
Worth Venture Partners, LLC70,954$78.0K
Royal Bank of Canada1,000$1.00K
Bank of America Corp14$15